Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K

Cancer immunology—analysis of host and tumor factors for personalized medicine

(2011) Shuji Ogino et al.   Nature Reviews Clinical Oncology

TNFα Cooperates with IFN-γ to Repress Bcl-xL Expression to Sensitize Metastatic Colon Carcinoma Cells to TRAIL-mediated Apoptosis

(2011) Feiyan Liu et al.   PLoS One

Induction of 90K-specific Cytotoxic T Lymphocytes for Colon Cancer Immunotherapy

(2011) Ji Hee Lee et al.   Immune Network

Glycoprotein 90K, downregulated in advanced colorectal cancer tissues, interacts with CD9/CD82 and suppresses the Wnt/ -catenin signal via ISGylation of  -catenin

(2010) J. H. Lee et al.   GUT

Increased Serum 90K and Galectin-3 Expression Are Associated with Advanced Stage and a Worse Prognosis in Diffuse Large B-Cell Lymphomas

(2009) Seok Jin Kim et al.   ACTA HAEMATOLOGICA

Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K

(2008) Renate Becker et al.   FASEB JOURNAL

Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia

(2008) Je-Jung Lee et al.   JOURNAL OF LEUKOCYTE BIOLOGY